Rep. Gilbert Ray Cisneros, Jr. Unloads Shares of Revvity Inc. (NYSE:RVTY)

Key Points

• Rep. Gilbert Ray Cisneros, Jr. sold $1,001–$15,000 of Revvity shares on October 27, according to a November 10 filing; the shares were held in a Bank of America trust account.
• Revvity reported quarterly earnings of $1.38 per share, beating the $1.30 consensus, while revenue of $728.9 million also exceeded estimates and rose 4.3% year over year.
• Analysts have a consensus “Hold” rating on Revvity, with a consensus price target of $133.86; six analysts rate it Buy and thirteen rate it Hold.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on October 27th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 11/2/2026.
• Purchased $1,001 - $15,000 in shares of argenex NASDAQ: ARGX on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Illumina NASDAQ: ILMN on 10/27/2026.
• Sold $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 10/27/2026.
• Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 10/27/2026.
• Purchased $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Micron Solutions OTCMKTS: MICR on 10/21/2026.
• Sold $1,001 - $15,000 in shares of Ciena NYSE: CIEN on 10/21/2026.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 10/21/2026.
• Purchased $1,001 - $15,000 in shares of Moderna NASDAQ: MRNA on 10/20/2026.

Revvity Stock Performance

NYSE:RVTY opened at $158.57 on Thursday. The firm has a market capitalization of $17.69 billion, a PE ratio of 28.67, a PEG ratio of 2.79 and a beta of 1.08. The stock's fifty day moving average is $149.49 and its 200 day moving average is $113.88. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $171.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.10 and a current ratio of 2.65.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.30 by $0.08. The company had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. Revvity had a net margin of 8.61% and a return on equity of 8.64%. Revvity's quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 earnings per share. On average, sell-side analysts anticipate that Revvity Inc. will post 5.42 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, January 22nd. Revvity's dividend payout ratio is presently 12.39%.

Institutional Trading of Revvity

Large investors have recently made changes to their positions in the stock. Group One Trading LLC purchased a new position in Revvity during the 3rd quarter worth $61,000. Westpac Banking Corp purchased a new stake in shares of Revvity in the 3rd quarter worth $1,167,000. Private Advisor Group LLC lifted its holdings in shares of Revvity by 16.5% in the 3rd quarter. Private Advisor Group LLC now owns 5,088 shares of the company's stock worth $778,000 after buying an additional 720 shares during the period. Boston Partners grew its position in shares of Revvity by 135.3% during the 3rd quarter. Boston Partners now owns 16,618 shares of the company's stock worth $2,541,000 after buying an additional 9,557 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its position in shares of Revvity by 74.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 55,613 shares of the company's stock worth $8,674,000 after buying an additional 23,806 shares in the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. KeyCorp increased their target price on shares of Revvity from $125.00 to $165.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Royal Bank Of Canada lifted their price target on shares of Revvity from $135.00 to $172.00 and gave the stock a "sector perform" rating in a research note on Wednesday, November 4th. Evercore reiterated an "outperform" rating on shares of Revvity in a report on Wednesday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of Revvity from $155.00 to $160.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. Finally, Bank of America reissued a "neutral" rating on shares of Revvity in a research note on Wednesday, November 4th. Six research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, Revvity has a consensus rating of "Hold" and a consensus price target of $133.86.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of the company's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 9,045 shares of company stock worth $1,281,439. Insiders own 0.85% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Revvity Company Profile

Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company's work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.